A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

However, Eli Lilly’s weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk’s market dominance. Novo’s stock has fallen nearly 20% year to date , compared to the ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership. Read more about LLY stock here.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.

Wall Street Bulls. Berenberg: Out of the gate, Berenberg analyst Kerry Holford lifted the firm’s price target on Eli Lilly stock by 17.6% to $1,000 from $850 and maintained a buy rating.

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. REUTERS Lilly’s stock was recently up 14% at $838.80 in ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA announced that a shortage of Mounjaro and Zepbound had been resolved.

Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds The drug maker’s net income came in at $2.76 billion, or $3.06 a share, up from $2.24 billion, or $2.48 a share, in the prior ...

Eli Lilly's R&D portfolio includes 77 projects, 22 of which are in Phase 3. At the same time, Novo has 47 projects , three of which have been submitted to regulators for approval, and 12 are in ...